Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Presidential Speakers

Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.  

Friday, June 13, 2025 - Presidential Session I

Immunotherapy (TCR related)

Prof.

Read more

Highlights from the SWG

EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

EHA-AAH Balkan Mini Hematology Tutorial 2021

EHA is joining forces with the Albanian Association of Hematology (AAH) to organize the EHA-AAH Balkan Hematology Mini Tutorial.

Read more